Skip to Content

Clinical Trials Detail

CDX110-06: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma

Objective
This is a clinical trial of investigational drug of Rindopepimut/GM-CSF which will be administered by injection.
IRB Protocol Number
13-1629
Principal Investigator(s)
DENISE M. DAMEK

Cancer Trials

  • Brain and Nervous System Tumors
Sponsor(s)
Celldex Therapeutics
Contact
MONICA ROBISCHON at 720-848-0661
or MONICA.ROBISCHON@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period will determine eligibility. You may be taking part in this study for up to 2 years. During the treatment phase you will have visits on day 1, day 15, day 29 and every 28 days thereafter for as long as your study doctor determines that you are still benefitting from the study drug. A follow-up period will include a clinic visit within 28 days of study drug discontinuation. After your disease has progressed, someone at the study site will contact you every 2 months to see what treatments for cancer you are currently receiving and how you are doing // Eligibility includes but are not limited to 18 years or older with Relapsed EGFRvIII-Positive Glioblastoma